首页> 外文会议>IFAC Symposium on Biological and Medical Systems >Continuous Glucose Monitoring: Using CGM to Guide Insulin Therapy Virtual Trials Results
【24h】

Continuous Glucose Monitoring: Using CGM to Guide Insulin Therapy Virtual Trials Results

机译:连续葡萄糖监测:使用CGM引导胰岛素治疗虚拟试验结果

获取原文

摘要

Continuous glucose monitoring (CGM) devices can measure blood glucose levels through interstitial measurements almost continuously (1-5min sampling period). However, they are not as accurate as glucose readings from blood measurements. The relation between tissue and blood glucose is dynamic and the sensor signal can degrade over time. In addition, CGM readings contains high frequency noise and can drift between measurements. However, maintaining continuous glucose monitoring has the potential to improve the level of glycemic control achieved and reduce nurse workload. For this purpose, a simple model was designed and tested to see the effect of inherent CGM error on the insulin therapy protocol, STAR (Stochastic TARgeted). An error model was generated from 9 patients that had one Guardian Real-Time CGM device (Medtronic Minimed, Northridge, CA, USA) inserted into their abdomen as part of an observation trial assesing the accuracy of CGM measurements compared to a blood gas analyser and glucometer readings. A resulting error model was then used to simulate the outcomes if the STAR protocol was guided by CGM values on 183 virtual patients. CGM alarms for hyper- and hypo-glycaemic region were included to improve patient safety acting as 'guardrails'. The STAR CGM protocol gave good performance and reduced workload by ~50%, reducing the number of measurements per day per patient from 13 to 7. The number of hypoglycaemic events increased compared to the current STAR from 0.03% <2.2mmol/L to 0.32%. However, in comparison to other published protocols it is still a very low level of hypoglycaemia and less than clinically acceptable value of 5% <4.0mmol/L. More importantly this study shows great promise for the future of CGM and their use in clinic. With the a newer generation of sensors, specifically designed for the ICU, promising less noise and drift suggesting that a reduced nurse workload without compromising safety or performance is with in reach.
机译:连续葡萄糖监测(CGM)器件可以通过几乎连续(1-5min采样期)通过间质测量来测量血糖水平。然而,它们与血液测量的葡萄糖读数不准确。组织和血糖之间的关系是动态的,并且传感器信号随着时间的推移可能降低。此外,CGM读数包含高频噪声,可以在测量之间漂移。然而,保持连续的葡萄糖监测有可能提高血糖控制的水平,并减少护士工作量。为此目的,设计了一个简单的模型,并测试并测试了固有的CGM误差在胰岛素治疗方案中的效果,明星(随机靶向)。从9名患者中产生了一个误差模型,该患者具有一个监护人实时CGM设备(Medtronic最小,Ca,USA),作为观察试验的一部分,与血气分析仪相比,分析CGM测量的准确性和凝血仪读数。然后,如果在183名虚拟患者上由CGM值指导,则使用产生的错误模型来模拟结果。包括超级和血糖区域的CGM警报,以改善患者安全作为“护卫舰”。明星CGM协议的性能良好,减少了〜50%,减少了每位患者的每天每天的测量数量为13至7。与当前星的低血糖事件的数量增加到0.03%<2.2mmol / L至0.32 %。然而,与其他公开的方案相比,它仍然是低血糖水平的低水平,并且少于临床上可接受的值5%<4.0mmol / L.更重要的是,这项研究对CGM的未来及其在诊所的使用表现出了很大的承诺。利用较新一代的传感器,专为ICU专为ICU设计,噪音和漂​​移的较少,表明护士工作量减少而不损害安全性或性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号